<DOC>
	<DOCNO>NCT01031927</DOCNO>
	<brief_summary>Several line evidence implicate glutamatergic dysfunction pathophysiology obsessive compulsive disorder ( OCD ) . Sarcosine , also know N-methylglycine , endogenous antagonist glycine transporter-I ( GlyT-I ) , potentiate glycine 's action glycine site N-methyl-D-aspartate ( NMDA ) receptor . In 10-week open-label trial , examine efficacy safety sarcosine treatment OCD patient .</brief_summary>
	<brief_title>N-methyl Glycine ( Sarcosine ) Treatment Obsessive Compulsive Disorder ( OCD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>primary OCD accord DSMIV least 1 year 's duration OC symptom minimum severity score ≥16 YaleBrown Obsessive Compulsive Scale drug naïve study entry free psychotropic medication least 8 week study entry , inadequately respond ongoing psychotropic medication study entry ( define YBOCS score ≧16 despite treatment maximum tolerate dose SRI medication least 8 week ) patient moderate severe depression define 21item Hamilton Depression Rating Scale score &gt; 17 , history bipolar disorder , schizophrenia , schizoaffective disorder , psychosis define DSMIV , significant risk suicide , clinically significant organic disease include cardiovascular , hepatic , pulmonary , neurologic , metabolic , renal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>obsessive compulsive disorder</keyword>
	<keyword>sarcosine</keyword>
	<keyword>glycine transporter I</keyword>
	<keyword>NMDA receptor</keyword>
</DOC>